Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024
For the Full year, the company expects revenue of $2,635 million to $2,735 million, net loss per share of $1,10 to $0.80.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.45 USD | +4.18% | -2.66% | -42.23% |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
1st Jan change | Capi. | |
---|---|---|
-42.23% | 2.11B | |
+44.83% | 2.77B | |
+115.18% | 703M | |
+12.20% | 484M | |
-46.76% | 66.82M |